Ann: Quarterly Activities Report and Appendix 4C, page-121

Hi All

I'm a substantial holder of RAP as in just outside the top 10 when you combine my holdings with an average buy price of about 18 cents. I therefore have more to lose than most on this forum.

I too was disappointed with the quarterly report today but not shocked but reading the commentary here you would think the world has ended. Rather than listening to all the opinions on HC I spoke with both Tony and Brian on the phone today to get some reassurance regarding my investment. They were both generous with their time which I thank them for.

I'm not going to quote anything that was said and these are all my personal views but lets just say after my conversation I've toped up. The big factor at play here is Medgate. If the trial goes well then we have just ticked a huge box. According to the Medgate website they do 6000 telehealth consultations per day. Make your own guess as to how many are respiratory. In Switzerland and Germany from what I understand the client does not pay, the insurance company does and that will include any Resapp fee. My understanding is that Medgate is very happy so far with the integration and are only a few weeks away from beginning the trial. Initial feedback from them is very positive. I ask myself this question: Does Medgate need Resapp? Does every other Telehealth company need Resapp. How else are they going to diagnose respiratory conditions over a phone or video consult. I'm personally willing to hold my investment on the belief that the Medgate deal will get done and be a success.

There are plenty of other issues to get side tracked by but for me this is the clincher. If Medgate sign then other Telehealth companies will surely have to follow. My numbers say we need 3000 downloads per day at net $5 to Resapp to break even. We could come close to this with Medgate in time and it wouldn't take many more companies to jump on board for us to become cashflow positive.

Once the pandemic calms down then we can start discussions with NHS and the like who will surely be very interested in learning about what we have to offer.

No doubt the company could be in a better position if a few things had gone our way but I'm holding AND I'm backing the current management team for at least the next 6 months to get this deal done.

My opinion only and please DYOR and good luck to all holders, we really deserve some wins soon.